Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer
Status:
Withdrawn
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: The monoclonal antibody trastuzumab can locate breast cancer cells that have HER2
on their surface and either kill them or deliver tumor-killing substances to them without
harming normal cells. Estrogen can stimulate the growth of breast cancer cells. Hormone
therapy using exemestane may fight breast cancer by reducing the production of estrogen.
Combining trastuzumab with exemestane may be an effective treatment for breast cancer with
high amounts of HER2.
PURPOSE: Phase II trial to study the effectiveness of combining trastuzumab with exemestane
in treating postmenopausal women who have metastatic or locally advanced HER2-positive breast
cancer.